Big Costs for Small Patients with Rare Diseases, Study Finds

Percentage of all child health spending that went to orphan drugs rose 65% in five years, while families’ portion rose even faster.

9:40 AM

Author | Kara Gavin

drawing of pills on lined paper in blue ink
Stephanie King

Only about one in every 170 children take them. But "orphan drugs" accounted for 1 in every 15 private insurance dollars spent on children's health care in the United States in 2018, according to a new study. That's up 65% from just five years before.

Even though insurance companies pay much of the cost of high-priced orphan drugs that treat rare childhood diseases, families' share of the cost has risen rapidly.

In fact, the study shows that out-of-pocket costs for these families were higher than those faced by adults who also take orphan drugs.

Some families spend thousands of dollars each year to buy orphan drugs, which are drugs that have received a special designation from the U.S. Food and Drug Administration. About 1 in 8 families paid more than $2,000 a year in 2018 – double the percentage who spent that much in 2013. 

The study, published in the October issue of the journal Health Affairs by researchers from the University of Michigan and Boston University, looks at private insurer payments and out-of-pocket spending on 526 orphan drugs. It used a database that every year included data about the drug costs of 4.4 to 5.8 million children age 17 and under.

The special FDA "orphan" designation is designed to incentivize drug companies to develop treatments for rare conditions. A company that receives the designation for its product has a greater amount of time when it has the exclusive rights to market the product and fend off competitors.

Certain drugs drove most of the increase

The researchers report that the prices for small-molecule drugs drove much of the increase in orphan drug spending, with a 162% rise in five years, compared with 16% for biologic drugs, which are derived from living organisms.

Just three drugs approved for the same condition account for more than 23% of all spending on orphan drugs for privately insured children in 2018, the analysis shows. All three – sold as Norditropin, Humatrope and Genotropin – were originally developed to boost the height of children with growth hormone deficiency.

But other research has shown that many children who don't have this rare condition also receive these three drugs through off-label prescribing aimed at boosting their height.

There are no clear guidelines for determining which children should receive the drugs, and insurance companies vary widely in their decisions about covering the cost of the drugs for such uses.

The new study was performed by Kao-Ping Chua, M.D., Ph.D., a pediatrician and health care researcher at Michigan Medicine, the academic medical center of the University of Michigan, and Rena Conti, Ph.D. of Questrom Boston University School of Business. Chua is a member of the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center and the U-M Institute for Healthcare Policy and Innovation; data for the study were accessed via IHPI data holdings.

Earlier this year, Chua, Conti and colleagues published their analysis of all FDA orphan drug designations between 2010 and 2018. They found that just over one-third were for pediatric conditions.

Paper cited: Health AffairsDOI: 10.1377/hlthaff.2020.00595

More Articles About: Lab Notes Children's Health Drug Discovery Health Care Delivery, Policy and Economics Pharmacy
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories doctor checking heart on patient
Health Lab
Leading experts release new guidelines to improve congenital heart surgery care for children
For the first time in more than 20 years, dozens of pediatric cardiologists, surgeons and other health professionals have come together to develop new guidelines intended to improve heart surgery care for this population of children and teens.
Health Lab
"Drawing Dad" becomes sensation throughout pediatric cancer unit
A form of art therapy for one dad brings joy to patients across his child's floor, also in-patient receiving treatments.
woman older with provider
Health Lab
Should older adults, with fewer years to live, keep getting cancer screenings?
Cancer screening guidelines increasingly factor in how long a person has left to live, to guide whether to continue or stop screening. A new poll explores older adults’ attitudes toward this approach.
stork with baby in bag with dollar sign
Health Lab
Childbirth associated with significant medical debt
Postpartum individuals are more likely to have medical debt than those who are pregnant, suggests a Michigan Medicine led study that evaluated collections among a statewide commercially insured cohort of 14,560 pregnant people and 12,157 people in the postpartum period.
purple all notifications on phone teen sleeping in bed with phone next to them
Health Lab
Study: Average teen received more than 200 app notifications a day
A Michigan Medicine expert explains more of a report’s key findings on cell phone use and how parents can support a healthy use of technology.
kids on the floor
Health Lab
Protecting children from poor air quality: 6 things to know
As smoke from Canada's historic wildfires triggers poor air quality alerts across the country, many parents worry about the impact on their child’s health, a national poll suggests. Here, a Michigan Medicine expert provides six ways to help reduce exposure.